Adverse events (CTC grades 3 and 4) during consolidation therapy
| . | HiDAC, % . | Multiagent CT, % . | P . |
|---|---|---|---|
| Documented infection | 20.9 | 14.5 | < .001 |
| Febrile neutropenia | 66.5 | 66.4 | .311 |
| Bleeding | 0.8 | 0.7 | .601 |
| Early death* | 0.9 | 0.6 | .389 |
| . | HiDAC, % . | Multiagent CT, % . | P . |
|---|---|---|---|
| Documented infection | 20.9 | 14.5 | < .001 |
| Febrile neutropenia | 66.5 | 66.4 | .311 |
| Bleeding | 0.8 | 0.7 | .601 |
| Early death* | 0.9 | 0.6 | .389 |
Death within 30 days after consolidation chemotherapy.